ABSTRACT − LB71350 is an HIV protease inhibitor with poor aqueous solubility and extensive first pass effect. The purpose of the present study was to test the feasibility of solid dosage form of LB71350 with improved bioavailability utilizing solid dispersion. Three different compositions with varying ratio of (LB71350: Gelucire 44/14: Tween 20) were studied. Capsule filling of these solid dispersion compositions was tested using a semi-automatic capsule filling system. Oral bioavailability in dog was tested. Chemical and physical stability at 4, 25 and 40 o C was monitored by HPLC assay, dissolution test, powder XRD and microscopy. The capsule filling system yielded uniform products of drug loading up to 10%. Oral bioavailability in dog was improved compared to the aqueous suspension of crystalline LB71350. Capsules were chemically stable for up to 6 months at 40 o C. However, there were temperature and composition dependent physical changes. Decrease in dissolution rates after storage at 40 o C was due to the polymorphic change. In conclusion, manufacturing process, bioavailability, and physico-chemical stability have been considered to propose a solid dispersion capsule formulation for the HIV protease inhibitor with poor physico-chemical properties. A new less soluble crystalline form identified during the physical stability test warrants further study.
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LB71350, an irreversible inhibitor of HIV protease, shows extensive first pass effect (Jeong et al., 1996) . To achieve good oral bioavailability of drugs with such an extensive first pass effect, it is crucial to maximize drug absorption rate so that metabolism can be saturated as quickly as possible. If drug absorption rate is slow, then little drug will reach the systemic circulation after efficient liver metabolism. Drug absorption rate is dependent on both permeability and solubility of the drug (Lipinski, 2000 , Stegemann et al., 2007 . When the aqueous solubility is very low, dissolution can be the rate-determining step in oral absorption (Curatolo, 1998 , Stegemann et al., 2007 . The aqueous solubility of LB71350 was less than 40 µg/ml. Not surprisingly, no significant plasma concentration was detected when an aqueous suspension of LB71350 was given to dog (Jeong et al., 1996) . For maximum drug absorption rate, cosolvent solution formulations were developed and used throughout the preclinical studies of LB71350. Cosolvent solution formulation composed of (LB71350: propylene glycol: ethanol: Tween 20) showed 30~50% bioavailability in dog.
In preclinical studies cosolvents such as ethanol or propylene glycol are frequently used to dissolve poorly water-soluble drugs (Waynforth, 1995) . However, cosolvent solution formulations are not pharmaceutically attractive and solid dosage form is preferred in clinical settings. A review by Strickley summarizes commercial oral formulations of molecules with solubility problems (2004) . Solid dispersion has been extensively explored to obtain solid dosage form of poorly water soluble drug (Vasconcelos et al., 2007 , Lee et al., 2010 . One particular approach is to use water-soluble polymers or solubilizing or emulsifying agents to formulate solid dispersions and then to encapsulate them in hard gelatin capsules (Sugimoto et al., 1998 , Yamada et al., 2000 , Cole et al., 2008 . Solid dispersions consist of a dispersion of the drug in an inert exipient matrix, where the drug could exist in either the finely divided crystalline, solubilized or amorphous states or a mixture thereof. High molecular weight polyethylene glycol (PEG) or Gelucire have been used frequently for that purpose because they can be filled into capsules as liquid at elevated temperature and solidify at room temperature (Aungst et al., 1997; Serajuddin et al., 1988; Leuner and Dressman, 2000, Hauss 2007 ).
The objective of the present study was to test the feasibility of solid dosage form of LB71350 with improved bioavailability utilizing solid dispersion. Crystalline LB71350 was mixed with melted Gelucire44/14 and Tween 20 at elevated J. Pharm. Invest., Vol. 41, No. 2 (2011) temperature and the resulting liquid mixture was filled into hard gelatin capsules. Plasma concentration profiles after administration of these capsules to dogs were compared with that of cosolvent solution formulation. Chemical and physical stability of capsules during storage at various temperatures was monitored by HPLC, dissolution tests, powder XRD and microscopy.
Materials and Methods

Materials
LB71350 was synthesized at LG Chemical. Gelucire 44/14, a saturated polyglycolized glyceride consisting of mono-, difatty acid esters of PEG was purchased from Gattefosse. Tween20 was purchased from Sigma. Hard gelatin capsules (size #0) were supplied by Seo-Heung Capsule(Seo-Heung, Korea). Other reagents were of analytical grade.
Solid dispersion capsule formulation
Gelucire44/14 in its original container was melted in an oven (70 o C) and shaken well before weighing out to ensure homogeneity. LB71350, melted Gelucire44/14, and Tween 20 in proportions given in Table I were homogenized with a homogenizer (ULTRA-TURRAX T25, JANKE & KUNKEL, IKALabortechnic). A water-jacketed reactor was assembled and the temperature of the water jacket was set at 50 o C with a thermostat. Solid dispersion prepared above was transferred into the reactor. The mixture in the reactor was stirred continuously with a mechanical stirrer to maintain the homogeneity of temperature and composition. Temperature control at 50 o C and stirring was required to maintain the flow necessary for filling the compositions F5 and F10. Solid dispersion F15 was too thick for testing with this filling system even at 50 o C. With Mini-Loader (Torpac, Fairfield, NJ), 100 empty capsules (#0) were loaded into Mini-Filler (Torpac). Flexible tubing was connected to the reactor and the solid dispersion in the reactor was drained into the capsule bodies. The flow was stopped between each capsule filling by pressing the tubing between fingers. After the solid dispersion in capsule bodies solidified at room temperature, the surface of the Mini-Filler plate was scraped with a clean plastic rod to remove excess filling and even out the drug loading. The capsules were then capped and removed from Mini-Filler. The surface of capsules was wiped out clean with low-lint wipers.
Content uniformity test
The content uniformity test was done for the capsules prepared as described above. Five capsules were taken randomly and their weights were measured and LB71350 content was determined by HPLC. Each capsule was opened and placed in 100 mL volumetric flask. The flask was filled with 50 mL methanol, shaken gently and sonicated for one hour. Then 50 ml of deionized water was added. The flask was shaken vigorously and was sonicated for another hour. The flask was left at room temperature for a while to set the temperature of the solution to room temperature. Methanol was added to the meniscus and the flask was shaken gently. The solution was filtered through 0.22 µm Nylon syringe filter and analyzed with HPLC according to the following condition:
HPLC : Hewlett-Packard series 1100 Table I were used for the dog pharmacokinetic study. For this study, the capsule composition F10 was prepared as described above using the semi-automatic capsule filling system. However, capsule filling of F15 was done by hand-filling the cooled solid dispersion in hard gelatin capsules (#13) using a spatula so that the filled weight of the mixture was adjusted to 300mg of LB71350 per capsule. As a comparison group to the capsule formulations, LB71350 was dissolved in the cosolvent solution (Propylene Glycol: Ethanol: Tween 20 = 85: 10: 5). The pharmacokinetics of LB71350 was studied in the male Beagle dog (7-10 kg). LB71350 was orally administered to dogs after 18 hour fasting at the dose of 15 mg/ kg or 300mg/dog via gavage (n=2-5). Blood samples were taken from the cephalic vein with a heparinized syringe at 0, 10, 30, 60, 120, 180, 240, 300, 360 min. After centrifuging whole blood, plasma was deproteinized. Plasma concentration of drug was determined by HPLC using following conditions (Jeong et al., 1997) C. After samples were removed from the storage at each sampling time point, they were temporarily stored at 4 o C before the assay and dissolution test. Samples were removed from the refrigerator and left at room temperature at least two hours prior to analysis. Extraction procedure for the assay was the same as described in the content uniformity test above.
Dissolution test for the capsules was performed using USP dissolution apparatus 1 (SR8PLUS, Hanson Research) at 37 o C.
Capsule composition F15 was not tested because it was not possible to produce capsules using the semiautomatic capsule filling system and only a small number of capsules in large capsule shells (#13) were prepared manually for dog pharmacokinetic study. One capsule in each dissolution basket was placed into 900 mL of 0.5% Tween 20 solution. The dissolution basket was rotated at 100 RPM. An aliquot of 0.3 mL was taken with 1 mL syringe at 15, 30, 60, 120, 180 min and then filtered through 0.2 µm nylon filter (MSI). Dissolution media were not replenished after each sampling. The filtrate was diluted with methanol/water solution (1/1) and the concentration of dissolved drug was determined by HPLC.
XRD powder patterns were recorded using D/Max-B X-ray diffractometer (Rigaku, Japan). Samples of solid dispersion removed from capsules were mounted on 0.2mm cavity sample holders. Continuous scan was done using following conditions:
Axis 
Light microscope
Light microscopic pictures were taken using Olympus BX60 (microscope) and Olympus PM-20 (exposure control unit). Table I summarizes the three different solid dispersion compositions tested for capsule formulations and Table II is the results of the content uniformity test for F5 and F10 capsules. Filled capsule weights and the capsule contents, either determined by HPLC assay or calculated from the filled capsule weights less the capsule shell weights, showed the relative standard deviation (RSD) of less than 5%. Capsule content assay done at later stability time points showed less than 10% changes from the initial values indirectly supporting the content uniformity of the capsule compositions F5 and F10 prepared according to the process described above (Table III) . F15 was not suitable for semi-automatic filling due to the thickness of the solid dispersion. These results demonstrate that scalingup of the present formulations with drug loading up to 10% will be feasible to yield capsules of acceptable content uniformity when a liquid or semi-solid filling machine is employed. Cole et al. described the advantages of employing hard gelatin capsules in laboratory scale testing to manufacture solid dosage form of liquid or semi solid formulations (2008): option to use laboratory scale equipment in-house to manufacture small batches during early development when drug substance supply is limited, no need for a time consuming gel mass preparation required for soft capsules, and better control in moisture than soft capsules. The capsule filling setup used in the present study well served those advantages.
Results and Discussion
Plasma concentration profiles in dog after oral administration of various formulations are shown in Figure. 1. Plasma concentration achieved with capsule formulation F10 was higher and more sustained than that with capsule formulation F15. Pharmacokinetic parameters are summarized in Table IV . Co-solvent solution formulation gave the highest plasma concentration. Taking the dog weight range of 7-10 kg into account, dose normalized Cmax and AUC of cosolvent solution formulation were at least five and ten-fold higher than those of capsule formulation F10, respectively. Cmax and AUC of the capsule formulation F15 were four to five times less than those of F10 tested at the same dose. The content of Tween20 seems to be critical for rapid dissolution of LB71350 in the gut after oral administration. Although the capsule formulations were less bioavailable than the co-solvent solution formulation, they were significant improvement over the aqueous suspension of crystalline LB71350 with which no plasma concentration was detected. Chemical stability of capsule formulations was monitored by HPLC assay. Table III showed slower dissolution rate and the decrease was more dramatic with formulation F10. These results indicate that the present capsule formulations should not be exposed above room temperature considering the physical instability demonstrated at 40 o C. Although slowdown of capsule dissolution after storage at 40 o C was attributed previously to cross-linking of the gelatin capsule shell (Joshi et al., 2004) , the dramatic decrease in dissolution rates observed in the present study is mainly due to the crystalline form changes during storage as explained below.
Powder XRD has been most widely used as a diagnostic tool for crystalline form of polymorphic changes of drug substance (Saleki-Gerhardt et al., 1994; Byrn et al., 1995; Byrn et al., 1999; Suryanarayanan, 1995) . C. Crystalline forms can change from a thermodynamically less stable to a more stable one and the latter has usually higher melting point and thus less solubility due to higher crystalline lattice energy (Hörter and Dressman, 1997) . The decrease in dissolution rates of F5 and F10 observed after storage at 40 o C (Figure 2) , then, imply that the new peaks detected in XRD (Figure 3 ) might be attributed to a new more stable and less soluble crystalline form. Interestingly, the dissolution rate of F10 decreased more than that of F5 after storage at 40 o C whereas there was no significant difference in XRD pattern of these two samples. It is possible that both F5 and F10 underwent crystalline form change at 40 o C but at relatively different rates and dissolution test was more sensitive than XRD in this case. The crystalline form used for the present study, designated as Form I, was obtained from the pilot scale synthesis and three batches of the same crystalline form had been produced consistently. In addition, LB71350 crystalline Form I was stable for at least two years at room temperature and for 6 months at 50 o C without any change in XRD patterns (Data not shown). With the knowledge that the crystalline Form I was stable as solid and the XRD of the solid dispersion formulations at the time of preparation did not show any sign of additional crystalline forms, one can only speculate that the crystal conversion Figure 4a ). These findings indicate that the crystalline Form I in F5 can change to a more stable new crystalline form at temperature between 4 and 40 o C and the conversion rate depends on the storage temperature. A drug product with practical shelf life cannot be realized when it shows change in crystalline form even at sub-ambient temperature. Therefore, the capsule composition F5 is not feasible for further development.
Distinct difference in XRD between the two formulations, F5 and F10, at 25 o C and 4 o C is very intriguing. The two capsule formulations were prepared with the same batch of drug substance and therefore it is unlikely that the drug crystals had any difference to begin with. Thermal history of the capsule formulation process was identical too. The only difference is the composition (Table I) . Heating the mixture of LB71350, Gelucire44/14 and Tween 20 to 50 o C during capsule-filling process is likely to result in supersaturated solution of LB71350 in these vehicles. When the liquid mixture cooled down after capsule filling, LB71350 would precipitate out of supersaturated solution and a saturated solution with excess drug crystals would appear at a given storage temperature. The XRD patterns of both F5 and F10 at initial time points or after 6 months at 4 o C indicate that these excess crystals were mainly crystalline Form I (Scan C of Figure 4a and 4b). What governs crystal form conversion is the presence of nuclei for the second crystalline form in the crystalline sample (Beckmann and Otto, 1996) . Although crystalline Form I was the only crystalline form at the time of capsule preparation within the detection limit of XRD, It is possible that nuclei for the new crystalline form were created during cooling after capsule filling of the solid dispersion. One hypothesis to explain the difference in the crystalline form conversion between F5 and F10 after storage at 25 o C is that the conversion was mediated through LB71350 dissolved in the vehicles and the difference in dissolution rates of LB71350 crystalline Form I at 25 o C in these two formulations, due to their difference in Tween20 content, influenced the course of dynamic equilibrium in the system. New crystalline nuclei that formed during cooling would ini- Figure 3 , which might be the results of high dissolution rates of LB71350 in both F5 and F10 at the elevated temperature. Although exact solubility of Form I and the new crystalline form in the given media at various temperatures or phase solubility equilibrium data would give more insight on the above hypothesis, attempts to obtain pure form of the newly found crystal by recrystallization from various organic solvent systems have failed.
Light microscope pictures ( Figure 5) show that the crystals after storage at 40 o C were much larger than those initially put into the system. Composition F5 after storage for 14 months at room temperature also showed larger crystals (Figure 5e ) compared to the initial samples (Figure 5a or 5b) . It is, therefore, not only the new crystalline form of less solubility that induced the dramatic decreases in the dissolution rates after storage at 40 o C, but also the larger particle size of these large crystals.
In conclusion, the present study demonstrated that improved bioavailability could be achieved for poorly soluble drug LB71350 using capsule formulations composed of solid dispersion. Their physical stability depended upon the capsule composition and the storage condition, which was critical to determine feasibility of these formulations. The composition F10 was the best among three solid dispersions tested considering its ease of manufacture, good oral absorption and the stability during storage at room temperature or below. Exposure to elevated temperature should be avoided to minimize the risk of crystalline form conversion to a more stable and less soluble crystalline form, which would result in the decrease in dissolution and compromise the product quality. The present study clearly demonstrated the impact of drug substance polymorphism during dosage form development.
